

Lawrence Steinman, MD

Steinman is Professor of Neurology, Neurological Sciences and Pediatrics at Stanford University and Chair of the Stanford Program in Immunology from 2001 to 2011. His research focuses on what provokes relapses and remissions in multiple sclerosis (MS), and on the quest for antigen specific therapy in type 1 diabetes, neuromyelitis optica and myasthenia gravis. He is taking forward a pivotal clinical trial with antigen specific tolerization therapy for type 1 diabetes.

Steinman was senior author on the 1992 *Nature* article that led to the drug Tysabri, approved for MS and Crohn's disease.

Dr. Steinman graduated from Dartmouth College, Magna Cum Laude in Physics. His MD is from Harvard Medical School. He was a post-doctoral fellow in chemical immunology fellow at the Weizmann Institute of Science. After neurology residency he remained on the faculty in 1980. He has received numerous honors, including the John M. Dystel Prize in 2004, the Javits Neuroscience Investigator Award from the NINDS twice, the Charcot Prize in MS research, and the Cerami Prize in Translational Medicine. Steinman is a member of the National Academy of Sciences, and the National Academy of Medicine.

Dr. Steinman holds 48 patents. He cofounded several biotech companies, including Neurocrine and Tolerion. He was a Director of Centocor from 1988 until its sale to Johnson and Johnson.

